Cronyxin Injection (100 ml)
Each ml of Cronyxin Solution contains 50 mg flunixin equivalent to 83 mg flunixin meglumine and excipients q.s. AnalgesicAnti-inflammatoryFlunixin meglumine is a potent, non-narcotic, non-steroidal, analgesic agent with anti-inflammatory activity. Antipyretic activity has been demonstrated in laboratory... Read more
Each ml of Cronyxin Solution contains 50 mg flunixin equivalent to 83 mg flunixin meglumine and excipients q.s.
Analgesic
Anti-inflammatoryFlunixin meglumine is a potent, non-narcotic, non-steroidal, analgesic agent with anti-inflammatory activity. Antipyretic activity has been demonstrated in laboratory animals. It is significantly more potent than pentazocine, meperidine and codeine as an analgesic in the rat yeast paw test. Flunixin is four times as potent on a mg per mg basis as phenylbutazone as measured by the reduction in lameness and swelling in the horse. Plasma half-life in horse serum is 1.6 hours following a single dose of 1.1 mg/kg. Measurable amounts are detectable in horse plasma at 8 hours post injection.
Visit www.myvetmeds.co.uk / equine / anti-inflammatory-equine / cronyxin-injection.htm
Product Description
About Cronyxin Injection (100 ml)
Each ml of Cronyxin Solution contains 50 mg flunixin equivalent to 83 mg flunixin meglumine and excipients q.s.
Analgesic
Anti-inflammatoryFlunixin meglumine is a potent, non-narcotic, non-steroidal, analgesic agent with anti-inflammatory activity. Antipyretic activity has been demonstrated in laboratory animals. It is significantly more potent than pentazocine, meperidine and codeine as an analgesic in the rat yeast paw test. Flunixin is four times as potent on a mg per mg basis as phenylbutazone as measured by the reduction in lameness and swelling in the horse. Plasma half-life in horse serum is 1.6 hours following a single dose of 1.1 mg/kg. Measurable amounts are detectable in horse plasma at 8 hours post injection.
Please note: images are for illustration purposes only and pack sizes/strengths and new packaging styles may not be reflected in the image shown.
Directions For Use
Directions for Use
The recommended dose for musculoskeletal disorders is 1.1 mg per kg (1 mL/45 kg) of bodyweight once daily. Treatment may be given by intravenous or intramuscular injection and repeated for up to 5 days. Intravenous studies show onset of activity is within 2 hours. Peak response occurs between 12 and 16 hours and duration of activity is 24 to 36 hours following intravenous and intramuscular administration.
The recommended dose for the alleviation of pain associated with equine colic is 1.1 mg per kg of bodyweight. Intravenous administration is recommended for prompt relief. Should colic symptoms recur, treatment may be repeated as necessary. Clinical studies show that pain symptoms were alleviated in 37% of treated horses within 15 minutes, and 74% within 30 minutes. The cause of colic should be determined and treated with concomitant therapy.
Active Ingredient
Cronyxin Injection (100 ml) ingredients
Each mL of Cronyxin ™ Solution contains 50 mg flunixin equivalent to 83 mg flunixin meglumine and excipients q.s.
Side Effects
Side effects of Cronyxin Injection (100 ml)
TOXICITY:
No toxic effects were observed in rats given intramuscular flunixin 4 mg/kg/day for 28 days. No adverse effects were seen in dogs given a single intramuscular injection of 50 mg/kg. Higher doses resulted in salivation, panting, emesis and tremors. No toxic effects were observed in monkeys given intramuscular doses between 3 and 30 mg/kg per day for 28 days. Prolonged parenteral treatment in horses at 2 mg/lb. bodyweight showed no untoward effects.
PRECAUTIONS:
Do not administer intra-arterially. Inadvertent intra-arterial injection may cause adverse reactions. Signs can be ataxia, incoordination, hyperventilation, hysteria, and muscle weakness. Signs are transient and disappear without antidotal medication within a few minutes.
REPRODUCTION:
The effect of Cronyxin ™ on reproduction in horses has not been determined.
Studies on reproduction in rats and rabbits have shown no teratogenicity.
COMPATIBILITY:
Studies to determine the activity of Cronyxin ™ when administered concomitantly with other drugs have not been conducted. Drug compatibility should be monitored closely in patients requiring adjunctive therapy.
WARNING:
This drug is not to be administered to horses that are to be slaughtered for food.
Additional Data
Cronyxin Injection (100 ml) specification
| Specification: | Detail: |
|---|---|
| Pack Size: | 100 ml |
| Brands: | Cross Vetrepharm |
| Product Form: | injection |
| External Link: | http://www.bionicheanimalhealth.com/Products.aspx?ProductID=30&PatientTypeID=7 |
